Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Current Leases: 2020-2025

Historic Current Leases for BIO-TECHNE (TECH) over the last 6 years, with Jun 2025 value amounting to $14.1 million.

  • BIO-TECHNE's Current Leases rose 2.12% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year increase of 2.12%. This contributed to the annual value of $14.1 million for FY2025, which is 9.12% up from last year.
  • As of FY2025, BIO-TECHNE's Current Leases stood at $14.1 million, which was up 9.12% from $12.9 million recorded in FY2024.
  • In the past 5 years, BIO-TECHNE's Current Leases registered a high of $14.1 million during FY2025, and its lowest value of $11.2 million during FY2023.
  • Its 3-year average for Current Leases is $12.7 million, with a median of $12.9 million in 2024.
  • In the last 5 years, BIO-TECHNE's Current Leases increased by 21.68% in 2021 and then declined by 6.11% in 2023.
  • Yearly analysis of 5 years shows BIO-TECHNE's Current Leases stood at $11.6 million in 2021, then climbed by 2.81% to $11.9 million in 2022, then fell by 6.11% to $11.2 million in 2023, then grew by 15.37% to $12.9 million in 2024, then increased by 9.12% to $14.1 million in 2025.